TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate the impact of a a real time teleassistance system in the clinical evolution of type 2 diabetic patients on self monitoring blood glucose in the Public National Primary Care System.


Options:
A: Arm Label: CONTROL group; Type: ACTIVE_COMPARATOR; Interventions: Other: Home Monitoring | Arm Label: ACTIVE group; Type: EXPERIMENTAL; Interventions: Other: Home Monitoring | Intervention Type: OTHER; Name: Home Monitoring; Assigned to Arm(s): ACTIVE group, CONTROL group
B: Arm Label: telemonitoring; Type: EXPERIMENTAL; Interventions: Device: Health Buddy system | Arm Label: usual care; Type: EXPERIMENTAL; Interventions: Device: Telemonitoring in patients with heart failure | Intervention Type: DEVICE; Name: Health Buddy system; Assigned to Arm(s): telemonitoring | Intervention Type: DEVICE; Name: Telemonitoring in patients with heart failure; Assigned to Arm(s): usual care
C: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine group; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine system | Intervention Type: DEVICE; Name: Telemedicine system; Assigned to Arm(s): Telemedicine group
D: Arm Label: TREATMENT Group; Type: ACTIVE_COMPARATOR; Interventions: Device: HF Pressure Measurement System | Arm Label: CONTROL Group; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DEVICE; Name: HF Pressure Measurement System; Assigned to Arm(s): TREATMENT Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to evaluate the impact of a a real time teleassistance system in the clinical evolution of type 2 diabetic patients on self monitoring blood glucose in the Public National Primary Care System.


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine group; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine system | Intervention Type: DEVICE; Name: Telemedicine system; Assigned to Arm(s): Telemedicine group
B: Arm Label: U-healthcare; Type: EXPERIMENTAL; Interventions: Device: U-healthcare service | Arm Label: SMBG group; Type: ACTIVE_COMPARATOR; Interventions: Device: SMBG group | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: U-healthcare service; Assigned to Arm(s): U-healthcare | Intervention Type: DEVICE; Name: SMBG group; Assigned to Arm(s): SMBG group
C: Arm Label: Telemedicine case management; Type: EXPERIMENTAL; Interventions: Device: Telemedicine Unit (HTU) | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: usual care | Intervention Type: DEVICE; Name: Telemedicine Unit (HTU); Assigned to Arm(s): Telemedicine case management | Intervention Type: OTHER; Name: usual care; Assigned to Arm(s): Usual care
D: Intervention Type: DEVICE; Name: OneTouch(r) UltraSmart(r); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Randomized, Placebo- Controlled Trial of Vigabatrin for Short Term Abstinence From Cocaine in Cocaine Dependent Parolees
Brief Summary: The primary objective of this study is to assess the efficacy of vigabatrin for the treatment of cocaine dependence, based on the twice-weekly qualitative urine toxicologies for cocaine. Based on two prior unblinded human studies and 15 years of animal studies, this 100 subject double- blind, randomized study is designed to show if with vigabatrin treatment but not placebo, even non-hospitalized cocaine dependent individuals with ready access to cocaine will become cocaine abstinent if they are self motivated to stop their cocaine habit. To accomplish this, cocaine dependent subjects will be randomly assigned to either a placebo or vigabatrin treatment group and treated for a nine week period. The primary hypothesis is that as compared to the placebo arm, the vigabatrin treatment arm will show a significant increase in the number of subjects who are abstinent for the final 3 weeks of the study.


Options:
A: Arm Label: FEM-CARE; Type: EXPERIMENTAL; Interventions: Behavioral: FEM-CARE | Arm Label: Health Promotion; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Promotion | Intervention Type: BEHAVIORAL; Name: FEM-CARE; Assigned to Arm(s): FEM-CARE | Intervention Type: BEHAVIORAL; Name: Health Promotion; Assigned to Arm(s): Health Promotion
B: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vigabatrin, Behavioral: Group therapy | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Group therapy | Intervention Type: DRUG; Name: Vigabatrin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B | Intervention Type: BEHAVIORAL; Name: Group therapy; Assigned to Arm(s): A, B
C: Arm Label: Parolee Comprehensive Care + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Comprehensive Care + Phone Coach | Arm Label: Parolee Brief HBV program + Phone Coach; Type: EXPERIMENTAL; Interventions: Behavioral: Parolee Brief HBV Program + Phone Coach | Arm Label: Usual Care Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual Care Group | Intervention Type: BEHAVIORAL; Name: Parolee Comprehensive Care + Phone Coach; Assigned to Arm(s): Parolee Comprehensive Care + Phone Coach | Intervention Type: BEHAVIORAL; Name: Parolee Brief HBV Program + Phone Coach; Assigned to Arm(s): Parolee Brief HBV program + Phone Coach | Intervention Type: BEHAVIORAL; Name: Usual Care Group; Assigned to Arm(s): Usual Care Group
D: Intervention Type: DEVICE; Name: Interactive computer based health-risk survey before doctor's visit; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double-Blind, Randomized, Placebo- Controlled Trial of Vigabatrin for Short Term Abstinence From Cocaine in Cocaine Dependent Parolees
Brief Summary: The primary objective of this study is to assess the efficacy of vigabatrin for the treatment of cocaine dependence, based on the twice-weekly qualitative urine toxicologies for cocaine. Based on two prior unblinded human studies and 15 years of animal studies, this 100 subject double- blind, randomized study is designed to show if with vigabatrin treatment but not placebo, even non-hospitalized cocaine dependent individuals with ready access to cocaine will become cocaine abstinent if they are self motivated to stop their cocaine habit. To accomplish this, cocaine dependent subjects will be randomly assigned to either a placebo or vigabatrin treatment group and treated for a nine week period. The primary hypothesis is that as compared to the placebo arm, the vigabatrin treatment arm will show a significant increase in the number of subjects who are abstinent for the final 3 weeks of the study.


Options:
A: Arm Label: Extended-release naltrexone (XR-NTX); Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Motivational Enhancement Counseling Only; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Motivational Enhancement Counseling | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-release naltrexone (XR-NTX) | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Counseling; Assigned to Arm(s): Motivational Enhancement Counseling Only
B: Arm Label: Depot Naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Depot naltrexone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual (TAU) | Intervention Type: DRUG; Name: Depot naltrexone; Assigned to Arm(s): Depot Naltrexone | Intervention Type: OTHER; Name: Treatment as Usual (TAU); Assigned to Arm(s): Placebo
C: Arm Label: Re-entry Modified Therapeutic Community (Re-entry MTC); Type: EXPERIMENTAL; Interventions: Behavioral: Re-entry Modified Therapeutic Community (Re-entry MTC) | Arm Label: Parole Supervision and Case Management; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Parole Supervision and Case Management | Intervention Type: BEHAVIORAL; Name: Re-entry Modified Therapeutic Community (Re-entry MTC); Assigned to Arm(s): Re-entry Modified Therapeutic Community (Re-entry MTC) | Intervention Type: BEHAVIORAL; Name: Parole Supervision and Case Management; Assigned to Arm(s): Parole Supervision and Case Management
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vigabatrin, Behavioral: Group therapy | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Group therapy | Intervention Type: DRUG; Name: Vigabatrin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B | Intervention Type: BEHAVIORAL; Name: Group therapy; Assigned to Arm(s): A, B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial Comparing TVT SECUR System (TVT S) and Trans Vaginal Obturator Tape (TVT-O) for Surgical Management of Stress Urinary Incontinence
Brief Summary: To compare the efficacy and complications of the TVT SECUR system (TVT S) and trans-vaginal obturator tape (TVT-O) procedures for the surgical management of female stress urinary incontinence.


Options:
A: Arm Label: TVT SECURE; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transvaginal obturator tape | Arm Label: TVT O; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transvaginal obturator tape | Intervention Type: PROCEDURE; Name: transvaginal obturator tape; Assigned to Arm(s): TVT O, TVT SECURE
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Ajust positioning | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: MiniArc positioning | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Procedure: TVT secur system positioning | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tension free vaginal ttape | Intervention Type: PROCEDURE; Name: MiniArc positioning; Assigned to Arm(s): 2 | Intervention Type: PROCEDURE; Name: TVT secur system positioning; Assigned to Arm(s): 3 | Intervention Type: PROCEDURE; Name: Ajust positioning; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Tension free vaginal ttape; Assigned to Arm(s): 4
C: Arm Label: Mini-sling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Mini-sling | Arm Label: Transobturator; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Transobturator | Intervention Type: PROCEDURE; Name: Mini-sling; Assigned to Arm(s): Mini-sling | Intervention Type: PROCEDURE; Name: Transobturator; Assigned to Arm(s): Transobturator
D: Arm Label: SIS single incision sling; Type: EXPERIMENTAL; Interventions: Device: SIS - Innovative fixation single incision sling | Arm Label: TOT trans obturator tape/sling; Type: ACTIVE_COMPARATOR; Interventions: Device: TOT - inside-out trans-obturator tape/sling | Intervention Type: DEVICE; Name: TOT - inside-out trans-obturator tape/sling; Assigned to Arm(s): TOT trans obturator tape/sling | Intervention Type: DEVICE; Name: SIS - Innovative fixation single incision sling; Assigned to Arm(s): SIS single incision sling

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Prone Positioning on Mortality in Patients With Severe and Persistent Acute Respiratory Distress Syndrome
Brief Summary: We project to test the effect of prone position on mortality in severe ARDS patients (PaO2/FiO2\<150 with FiO2 \> or = 0.6 and positive end-expiratory pressure \> or = 5 cmH2O). Ventilator will be set in accordance with current standards aiming at protecting the lungs from VALI. Patients will be randomized into two arms: prone group in which proning will be realized for at least 16 hours a day and supine group in which patients will stay in a semi-recumbent position. Primary end-point is 28-day mortality of all causes. Secondary end-points are 90-day mortality of all causes and incidence of ventilator-acquired pneumonia. Study sample was calculated to detect ability of proning to reduce mortality from 60 to 45% percent, at one-tailed alpha error of 5% and power of 90% and 230 patients are needed in each arm.


Options:
A: Intervention Type: PROCEDURE; Name: Control Ventilation Strategy; Assigned to Arm(s): N/A
B: Arm Label: HFO-TGI; Type: EXPERIMENTAL; Interventions: Other: High Frequency Oscillation and Tracheal Gas Insufflation | Arm Label: CMV; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: High Frequency Oscillation and Tracheal Gas Insufflation; Assigned to Arm(s): HFO-TGI
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: prone position | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone position; Assigned to Arm(s): A
D: Arm Label: Conventional Ventilation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Lung Protective Ventilation | Arm Label: High Frequency Oscillation; Type: EXPERIMENTAL; Interventions: Device: SensorMedics 3100B High Frequency Oscillatory Ventilator | Intervention Type: DEVICE; Name: SensorMedics 3100B High Frequency Oscillatory Ventilator; Assigned to Arm(s): High Frequency Oscillation | Intervention Type: PROCEDURE; Name: Lung Protective Ventilation; Assigned to Arm(s): Conventional Ventilation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Prone Positioning on Mortality in Patients With Severe and Persistent Acute Respiratory Distress Syndrome
Brief Summary: We project to test the effect of prone position on mortality in severe ARDS patients (PaO2/FiO2\<150 with FiO2 \> or = 0.6 and positive end-expiratory pressure \> or = 5 cmH2O). Ventilator will be set in accordance with current standards aiming at protecting the lungs from VALI. Patients will be randomized into two arms: prone group in which proning will be realized for at least 16 hours a day and supine group in which patients will stay in a semi-recumbent position. Primary end-point is 28-day mortality of all causes. Secondary end-points are 90-day mortality of all causes and incidence of ventilator-acquired pneumonia. Study sample was calculated to detect ability of proning to reduce mortality from 60 to 45% percent, at one-tailed alpha error of 5% and power of 90% and 230 patients are needed in each arm.


Options:
A: Arm Label: Semirecumbent position; Type: ACTIVE_COMPARATOR; Interventions: Other: lateral-Trendelenburg position | Arm Label: lateral-Trendelenburg position; Type: EXPERIMENTAL; Interventions: Other: lateral-Trendelenburg position | Intervention Type: OTHER; Name: lateral-Trendelenburg position; Assigned to Arm(s): Semirecumbent position, lateral-Trendelenburg position
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: prone position | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone position; Assigned to Arm(s): A
C: Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Procedure: Trendelenburg position | Intervention Type: PROCEDURE; Name: Trendelenburg position; Assigned to Arm(s): Single arm
D: Arm Label: Repetitive recruitment with PEEP; Type: EXPERIMENTAL; Interventions: Procedure: Repetitive recruitment with PEEP | Arm Label: One recruitment with PEEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: One recruitment with PEEP | Intervention Type: PROCEDURE; Name: Repetitive recruitment with PEEP; Assigned to Arm(s): Repetitive recruitment with PEEP | Intervention Type: PROCEDURE; Name: One recruitment with PEEP; Assigned to Arm(s): One recruitment with PEEP

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Prone Positioning on Mortality in Patients With Severe and Persistent Acute Respiratory Distress Syndrome
Brief Summary: We project to test the effect of prone position on mortality in severe ARDS patients (PaO2/FiO2\<150 with FiO2 \> or = 0.6 and positive end-expiratory pressure \> or = 5 cmH2O). Ventilator will be set in accordance with current standards aiming at protecting the lungs from VALI. Patients will be randomized into two arms: prone group in which proning will be realized for at least 16 hours a day and supine group in which patients will stay in a semi-recumbent position. Primary end-point is 28-day mortality of all causes. Secondary end-points are 90-day mortality of all causes and incidence of ventilator-acquired pneumonia. Study sample was calculated to detect ability of proning to reduce mortality from 60 to 45% percent, at one-tailed alpha error of 5% and power of 90% and 230 patients are needed in each arm.


Options:
A: Arm Label: Focal ARDS; Type: EXPERIMENTAL; Interventions: Procedure: Mechanical ventilation | Arm Label: non focal ARDS; Type: OTHER; Interventions: Procedure: Mechanical ventilation | Intervention Type: PROCEDURE; Name: Mechanical ventilation; Assigned to Arm(s): Focal ARDS, non focal ARDS
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: prone position | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone position; Assigned to Arm(s): A
C: Arm Label: Minimal alveolar distension; Type: ACTIVE_COMPARATOR; Interventions: Device: Setting of positive end-expiratory pressure | Arm Label: Maximal alveolar distension; Type: EXPERIMENTAL; Interventions: Device: Setting of positive end-expiratory pressure | Intervention Type: DEVICE; Name: Setting of positive end-expiratory pressure; Assigned to Arm(s): Maximal alveolar distension, Minimal alveolar distension
D: Arm Label: PHARLAP ventilation group; Type: EXPERIMENTAL; Interventions: Other: PHARLAP mechanical ventilation strategy | Arm Label: Control group ventilation; Type: ACTIVE_COMPARATOR; Interventions: Other: Control group mechanical ventilation strategy | Intervention Type: OTHER; Name: PHARLAP mechanical ventilation strategy; Assigned to Arm(s): PHARLAP ventilation group | Intervention Type: OTHER; Name: Control group mechanical ventilation strategy; Assigned to Arm(s): Control group ventilation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Prone Positioning on Mortality in Patients With Severe and Persistent Acute Respiratory Distress Syndrome
Brief Summary: We project to test the effect of prone position on mortality in severe ARDS patients (PaO2/FiO2\<150 with FiO2 \> or = 0.6 and positive end-expiratory pressure \> or = 5 cmH2O). Ventilator will be set in accordance with current standards aiming at protecting the lungs from VALI. Patients will be randomized into two arms: prone group in which proning will be realized for at least 16 hours a day and supine group in which patients will stay in a semi-recumbent position. Primary end-point is 28-day mortality of all causes. Secondary end-points are 90-day mortality of all causes and incidence of ventilator-acquired pneumonia. Study sample was calculated to detect ability of proning to reduce mortality from 60 to 45% percent, at one-tailed alpha error of 5% and power of 90% and 230 patients are needed in each arm.


Options:
A: Arm Label: Focal ARDS; Type: EXPERIMENTAL; Interventions: Procedure: Mechanical ventilation | Arm Label: non focal ARDS; Type: OTHER; Interventions: Procedure: Mechanical ventilation | Intervention Type: PROCEDURE; Name: Mechanical ventilation; Assigned to Arm(s): Focal ARDS, non focal ARDS
B: Intervention Type: PROCEDURE; Name: pulmonary artery catheter; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: central venous catheter; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fluid management; Assigned to Arm(s): N/A
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: prone position | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: prone position; Assigned to Arm(s): A
D: Arm Label: One Group; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center, Open-Label, Randomized Study to Assess the Safety and Contraceptive Efficacy of Two Doses ( in vitro12 µg/24h and 16 µg/24h) of the Ultra Low Dose Levonorgestrel Contraceptive Intrauterine Systems (LCS) for a Maximum of 3 Years in Women 18 to 35 Years of Age and an Extension Phase of the 16µg/24h Dose Group (LCS16 Arm) up to 5 Years
Brief Summary: This is a study on a new low dose levonorgestrel contraceptive intrauterine systems (LCS). The purpose of the study is to investigate which of the 2 administered doses is the lowest effective intrauterine dose of Levonorgestrel (LNG) administered via the LCS for contraception during 3 years. The study was amended: the LCS16 arm will be extended up to 5 years


Options:
A: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: LNG-IUS (BAY 86-5028) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: 68 mg etonorgestrel implant for subdermal use (Nexplanon) | Intervention Type: DRUG; Name: LNG-IUS (BAY 86-5028); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: 68 mg etonorgestrel implant for subdermal use (Nexplanon); Assigned to Arm(s): Arm 2
C: Arm Label: LCS12; Type: EXPERIMENTAL; Interventions: Drug: LCS12 | Arm Label: LCS16; Type: EXPERIMENTAL; Interventions: Drug: LCS16 | Intervention Type: DRUG; Name: LCS12; Assigned to Arm(s): LCS12 | Intervention Type: DRUG; Name: LCS16; Assigned to Arm(s): LCS16
D: Arm Label: Contraceptive vaginal ring; Type: ACTIVE_COMPARATOR; Interventions: Device: NuvaRing | Arm Label: Oral contraceptive pill; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ortho Tri-cyclen Lo | Intervention Type: DRUG; Name: Ortho Tri-cyclen Lo; Assigned to Arm(s): Oral contraceptive pill | Intervention Type: DEVICE; Name: NuvaRing; Assigned to Arm(s): Contraceptive vaginal ring

Answer: C